Kornimate/medical-research-clean huggingface dataset:
the multi center, randomized, double-blind, positive controlled study of bicyclol in the treatment of acute dili

Conditions: Drug-Induced Acute Liver Injury

Summary: the study adopted the superiority design of multi center, randomized, double-blind, positive control drug, dose finding, using two simulation skills. the qualified subjects, according to the ratio of 1:1:1, were randomized into low dose group, high dose group and positive drug control group, and received a treatment course of 4-8 weeks, all individuals were followed up for 4 weeks after drug withdrawal.

explore the safety and efficacy of different doses of bicyclol in treatment of acute drug-induced liver injury using polyene phosphatidylcholine capsule as the positive control drug. the study adopted the design of multi center, randomized, double-blind, dose finding, positive control drug, superiority test, using two simulation skills. the qualified subjects, according to the ratio of 1:1:1, were randomized into low dose group and high dose group and positive drug control group, and received a treatment course of 4-8 weeks, all individuals were followed up for 4 weeks after drug withdrawal.

Eligibility criteria:
inclusion criteria: 1. 18-75 years old, male or female; 2. meet the standard of clinical diagnosis of acute drug-induced liver injury, the rucam causality scale score is more than or equal to 6 points. if the rucam causality scale score is 3-5,the subject needs three liver disease experts to confirm whether he is dili patient, at least two of three liver disease experts should have the same judgment; 3. the serum alt is between 3and 20 times uln, but tbil is less than or equal to 2 times uln; 4. liver biochemical indexes(alt,ast,alp,ggt,tbil,albumin,prothrombin time) abnormalities lasted less than 90 days; 5. patients can understand the nature of the experiment, the nature of the disease, the characteristic of drugs, related treatment methods and the risk they may need to bear if they participate in the test, and sign the informed consent. exclusion criteria: 1. occurrent liver injury caused by other reasons, such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease etc; 2. acute liver failure or liver function decompensation patient perform, such as hepatic encephalopathy, ascites, albumin is less than or equal to 35g / l, the international standardized ratio (inr) of thrombin is more than 1.5; 3. serum creatinine is more than 1.5 times uln; 4. severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases; 5. taking drugs that may affect observation of curative effect of the experimental drug during the study; 6. allergy or intolerance to experimental drugs; 7. with no ability to express their complaints, such as mental illness and severe neurosis patient; 8. the patient can not cooperate and poor compliance; 9. pregnant and lactating women or women preparing for pregnancy; 10. the patient participated in other clinical trials in 3 months before entering this study; 11. using other liver-protective drugs except ursodeoxycholic acid or ademetionine within three days; 12. the researchers believe not suitable.
a study of sertraline compared with paroxetine in the treatment of panic disorder

Conditions: Panic Disorder

Summary: to evaluate the efficacy and safety of sertraline compared to paroxetine in patients with panic disorder.


Eligibility criteria:
inclusion criteria: * patient who meets diagnosis of panic disorder (with or without agoraphobia) according to diagnostic and statistical manual of mental disorders, fourth edition (dsm iv). * patients must have experienced at least 4 panic attacks within 4 weeks before screening. * at baseline patients with panic disorder of total score of 18 or higher on the panic and agoraphobia scale (clinician rated version). exclusion criteria: * patients who concurrently have bipolar disorder, schizophrenia, delusional disorder, epilepsy, major depression disorder (mdd), obsessive compulsive disorder (ocd), seasonal affective disorder (sad) or general anxiety disorder (gad) according to the dsm-iv criteria. * patients who concurrently have depression/depressive state, anxiety disorder and generalized anxiety disorder may be included in the study if the primary diagnosis is identified to be panic disorder * patients with the total score of at least 18 on the hamilton depression rating scale (ham-d) (items 1 to 17) at the start of screening (visit 1) * patients who require concomitant drug therapy with psychotropic agents (including benzodiazepines) and monoamine oxidase inhibitor during the period of the study.

Keywords: panic disorder
a prospective study of evaluation of minor bleeding and utility of bleeding criteria in acute-on-chronic liver failure patients in china

Conditions: Liver Failure, Acute on Chronic; Hemostatic Disorder

Summary: ineffective hemostasis or a paradoxical prothrombotic state of acute-on-chronic liver disease (aclf) has been well established. however, the minor and major bleeding events has not been described yet. we observe the patients' major and minor bleeding events and use 4 criteria, which include barc, isth, timi, gusto ,to evaluate the incident rate of bleeding events in aclf patients and pre-aclf patients.


Eligibility criteria:
inclusion criteria: * patient with previously or undiagnosed chronic liver disease/cirrhosis; * serum bilirubin higher than 3 mg/dl (51 mmol/l) or alt\>10uln（male 300 u/l; female 200 u/l) exclusion criteria: * those who had or been diagnosed hepatocellular carcinoma or other types of malignancies; * pregnancy; * obstructive biliary diseases or other disease lead to bilirubin evaluation; * using steroid or immunosuppressant in 4 weeks; * prior surgeries including splenectomy，subtotal splenectomy and disconnection，liver transplantation. * combine with other disease lead to organ failure including heart failure (nyha iv),respiratory failure（pao2\<60mmhg),renal insufficiency(ckd 5) and conscious disturbance (gcs\<8)

Keywords: liver failure
comparison of topical use of platelet-rich plasma versus hyaluronic acid during endoscopic fat graft myringoplasty: a randomized clinical study

Conditions: Chronic Suppurative Otitis Media

Summary: this study aimed to compare the effect of adding ha versus prp to endoscopic fgm in cases of small or medium-sized central tm perforation in the form of: 1. evaluation of the graft uptake rate. 2. evaluation and comparing audiological outcomes. 3. finding out intraoperative and postoperative morbidity.

tympanic membrane (tm) perforations result in recurrent middle ear infection and hearing loss. both these hazards can be prevented by the reconstructive surgery of the tympanic membrane. fat graft myringoplasty (fgm) has been reported as a suitable procedure to close long-standing tm perforations fgm is an efficient, safe and potentially fast method for tm perforation repairing with a success rate varies from 79% to 91%..many researches was done to use supporting material in myringoplasty saliba et al used hyaluronic acid fat graft myringoplasty \[hafgm\] and results in a higher success rate than using fgm alone. el-anwar et al proved that topical autologous platelet-rich plasma(prp) application during myringolpasty is safe, efficient and enhances healing of tm perforation prp includes many autologous growth factors that have significant functions like cell proliferation, migration, and angiogenesis. fibrin and fibronectin are essential proteins in prp that provide the structural support needed for the cell migration, cell proliferation, and 3-dimensional growth of tissues. ha has been shown to play a role in cellular signaling, leukocyte growth and migration, cell adhesion and biological remodeling and is mainly involved in tissue healing with a central role in modulating inflammatory responses also, its absorption of water causes expansion in volume and formation of a viscoelastic gel which constitutes a favorable scaffold for tissue regeneration and remodeling .

Eligibility criteria:
inclusion criteria: * patients with central small or median sized dry perforation * aged between 14 and 50 years * in cases of csom the perforation must be dry with no otorrhea with healthy middle ear mucosa for at least three month without medications * conductive gap on audiometry not more than 40 db. exclusion criteria: * discharging csom . * concurrent urti . * csom with dry marginal perforation * patients who didn't come for follow up. * age less than 14 or more than 50. * unsafe csom with cholesteatoma, apparent retraction pockets, granulations, or extensive myringosclerosis reaching the edges of the perforation. patients * patients who are suspected of having eustachian tube dysfunction. * suspected ossicular pathology in safe csom if the abg \&gt; 40db. * patients with history of previous ear surgery. * patients unfit for surgery or having chronic medical illness. * narrow external auditory canal. * patients who refused to enrolled in our study * patients with sensorineural hearing loss or only functioning ear.

Keywords: csom chronic suppurative otitis media tympanic membrane perforation tm perforation myringoplasty tympanoplasty endoscopic tympanoplasty
biomarker discovery and application in bladder cancer

Conditions: Bladder Cancer

Summary: the investigators' long-term objective is to research and develop innovative new tests which diagnostic laboratories can use to 1) detect methylated dna targets, 2) tumor specific antigens, and 3) markers of bacillus calmette-guerin (bcg) treatment in patient urine samples. the investigators plan to detect methylated dna targets and control targets by methylation-specific polymerase chain reaction (mspcr) on dna isolated from urine samples from bladder cancer positive and negative patients to determine its sensitivity and specificity in detecting bladder cancer. the investigators plan to use patient sera as a tool to detect tumor specific antigens expressed by bladder cancer cell lines. once a bladder tumor specific protein is identified, the investigators will assess its presence in the urine of bladder cancer patients and absence in healthy patients by enzyme-linked immunosorbent assay (elisa). the investigators plan to use both in vitro models and patient clinical samples to elucidate the role of bladder epithelial cells in mediating bcg immunotherapy and identify biomarkers of treatment effectiveness. once a biomarker is identified, the investigators will assess its presence in the urine of bladder cancer and absence in healthy patients. once the investigators determine the feasibility of these tests, the investigators will further perform an extensive clinical study, comparing the tests to existing diagnostic methods. this study will provide the foundation for fda approval, which is required for tests to become widely accepted tools for clinicians to use in bladder cancer diagnosis. the investigators' tests will improve early detection of bladder cancer, thereby improving patient health and decrease cancer deaths, a key mission of the national institutes of health.


Eligibility criteria:
inclusion criteria: * over 18 years old exclusion criteria: * no exclusion criteria
ovarian hyperstimulation syndrome in patients triggered by gnrh agonist for excessive follicular response

Conditions: Ovarian Hyperstimulation Syndrome; Hypercoagulability

Summary: in the literature, the risk of moderate to severe ohss is 3 to 6% and reaches 31% in high risk populations 9 days after oocyte triggering with hcg. many studies report no or a markedly decreased risk of ohss after triggering ovulation with a gnrh agonist. however, criteria to define ohss are rarely explained and ohss itself is not thoroughly asserted. it is well known that ohss is associated with hypercoagulability. however, no study after triggering with a gnrh agonist assessed haemostasis in these high-risk patients with high circulating estradiol levels. study design, size, duration: in a french academic reproductive medicine centre, a systematic prospective observational follow-up of all patients triggered by gnrh agonist for excessive follicular response will be conducted. participants/materials, setting, methods: all patients undergoing antagonist protocol and at high risk of ohss (estradiol level ≥ 3000 pg/ml and/or more than 20 follicles ≥ 11mm on the day of triggering) will be triggered by gnrh agonist. no luteal phase support and a "freeze-all" strategy will be performed. on the day of oocyte retrieval (t0), at 48h (t1) and at day 7 (t2), ohss and hypercoagulability will be systematically assessed. haemostasis data will be compared to the initial status of each patient.

seventy-five patients will be required for this study.

Eligibility criteria:
inclusion criteria: * estradiol level ≥ 3000 pg/ml and/or more than 20 follicles ≥ 11mm on the day of triggering and antagonist protocol exclusion criteria: * agonist protocol no health assurance estradiol level \< 3000 pg/ml and less than 20 follicles ≥ 11mm on the day of triggering

Keywords: gnrh agonist triggering
retrospective study in a nsclc m+ p

Conditions: EGFR Mutated Non-small Cell Lung Cancer Patients

Summary: this is a national, multicentre, non-interventional, retrospective study to be carried out in the oncology settings of approximately 15-20 spanish hospitals. at each participant hospital, all patients recently diagnosed with advanced egfr mutated nsclc (both newly or with recurrent disease , without previous treatment for metastatic disease) from april 2010 to december 2011 will be included as study population. information about the follow-up of the patients during a minimum of 12 months after diagnosis will be collected.

observational retrospective study to describe the management of advanced or metastatic egfr mutated non-small cell lung cancer patients in spain

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed newly locally advanced or metastatic nsclc (stage iiib/iv) * confirmed egfr mutation by a validated test * availability of medical record exclusion criteria: * participating on a blinded randomized clinical trial at any time during the study period * pregnant women (due to they do not reflect daily clinical practice)

Keywords: egfr, lung cancer, mutated
the effect of reiki and massage with sage oil on primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study was a randomized controlled trial. it included young girls with primary dysmenorrhea in a district located in the south of turkey and was conducted between march 01, 2021 and june 30, 2021. the sample size of this research was decided by performing a power analysis in the power statistical program. considering the parameters of the groups, the effect size was calculated to be 0.5003604. since α was found to be 0.05 and power (1 - β) was 0.95, a total number of 66 participants were distributed into three equal groups (sage oil massage: 22, reiki: 22, control: 22). considering the possibility of case losses, 30 participants were included in each group; finally, a total of 90 people were included in the study. for data collection, a questionnaire regarding sociodemographic characteristics and the visual analog scale (vas) were used. reiki and massage with sage oil were applied for 30 minutes, and no application was performed on the control group.


Eligibility criteria:
inclusion criteria: being female not married exclusion criteria: psychiatric problem communication barrier those who refuse to work

Keywords: midwifery, nurse, alternative therapies
floseal in crs and hipec

Conditions: Peritoneal Carcinomatosis

Summary: introduction modern treatment of peritoneal carcinomatosis (pc) combines an aggressive cytoreductive surgery (crs) of all macroscopic disease and hyperthermic intraperitoneal chemotherapy (hipec) performed at the time of surgery. it is considered a high risk procedure and post-operative intra-abdominal bleeding is a major issue as it can delay recovery and promote intra-abdominal infections. in most severe cases (10 to 20% of patients), a second surgery to control the bleeding will be necessary. major causes of bleeding are : radical resection, extensive peritonectomy, length of surgery, massive transfusion and use of hipec. to reduce the risk of intra-abdominal hemorrhage, many strategies have been tried and one of these is the liberal use of floseal, but there is no data in this particular field of interest. over the last 18 months, the investigators have started to use floseal in all their cases with large pc and they have observed a dramatic reduction in the rate of reoperation for bleeding and probably secondarily, in the use of blood products, but this has not been measured. hypothesis floseal can reduce the risk of bleeding after crs and hipec procedure. primary objective to evaluate if the use of floseal can reduce the risk of reoperation after crs and hipec procedure in the treatment of pc. secondary objectives * to evaluate if the use of floseal can reduce operative blood loss. * to evaluate if the use of floseal can reduce the need of blood products after crs and hipec procedure. * to evaluate if the use of floseal can have an impact on other common surgical complications (which can be indirectly bleeding related). * to evaluate if the use of floseal can have an impact on length of hospital stay.


Eligibility criteria:
inclusion criteria: * male and female patients older than 18 year old * all cases of pc regardless of primary tumour (colorectal carcinoma, peritoneal mesothelioma, appendiceal carcinoma etc.) exclusion criteria: * prophylactic hipec * peritoneal carcinomatosis index (pci) \< 5
promoting breast cancer screening in women who survived childhood cancer

Conditions: Cancer

Summary: the purpose of this study is to empower women to improve their health in two very important areas: breast and heart health. this twelve-month study will compare two methods of informing participants about potential health risks and ways to stay healthy. the empower study has been designed for adult women who were treated for a childhood cancer with chest radiation.


Eligibility criteria:
inclusion criteria: * participant in the ccss cohort * diagnosed with a childhood cancer prior to 21 years of age * treated with \> 20 gy of chest radiation (mantle, mediastinal, lung, or chest) * age 25-49 years at time of enrollment into the study * interval from chest radiation to the time of enrollment of \> 8 years * no mammogram or other breast imaging study in the 24 months prior to enrollment * english-speaking - the university of colorado amc denver and mskcc group are not capable of or equipped for conducting a brief motivational interviews by telephone in another language. exclusion criteria: * diagnosed with breast cancer * participated in the project vision feasibility study (exposed to part of the intervention)

Keywords: questionnaires telephone counseling session 10-104 childhood cancer survivor women post chest radiation
acoustic assessment of nebulized epinephrine versus albuterol for rsv bronchiolitis- a double blind study

Conditions: Rsv Bronchiolitis

Summary: bronchiolitis is a common disease of infancy and a main reason for infants' hospital admissions in the first 2 years of life. the main cause of bronchiolitis is rsv (respiratory syncytial virus). though, treatment is mainly supportive, the treatment benefit of nebulized epinephrine or albuterol has been largely debated for the past years. most of the clinical studies used clinical parameters to detect and compare the effectiveness of such medical interventions. in this study we will use non invasive computerized method of wheeze and crackles quantification to compare the effectiveness of nebulized epinephrine vs albuterol in rsv bronchiolitis.

inpatient infants younger than 2 years of age with first episode of rsv bronchiolitis will be randomly assigned to treatment with nebulized epinephrine (1 mg diluted with 3 ml of 0.9% saline) or nebulized albuterol (2.5 mg diluted with 3.5 ml of 0.9% saline). both solutions will be provided in identical containers. clinical assessment and clinical score will be done before treatment, 10 and 30 minutes after treatment. the following parameters were recorded at each time point, wheezing, respiratory distress, o2 saturation, respiratory rate and heart rate. computerized lung sounds as well, will be recorded before treatment, 10 and 30 minutes after treatment via 4 contact sensors attached to the chest.

Eligibility criteria:
inclusion criteria: * under one year of age * first episode of wheezing and dyspnea * rsv antigen detected by elisa * parents signed informed consent. exclusion criteria: * infants with chronic lung disease * cardiac disease * other chronic conditions.
telenursing system by providing health education and lifestyle modification among diabetic patients in bangladesh

Conditions: Diabetes Mellitus

Summary: the global burden of chronic diseases is increasing and becoming a public health issue throughout the world. the use of telenursing is increasing significantly during and after the covid-19 pandemic to treat and prevent chronic diseases. study objectives: the objective of this study is to apply the self-management telenursing program and telenursing system developed by the researchers to bangladesh and to evaluate its feasibility and efficacy (improved diabetes control in participants). method: this is a pilot, quasi-experimental pre- and post-intervention study. diabetes patients who will attend the grameen primary health care centers (phcs) in bangladesh will be enrolled. investigators include patients who have been diagnosed with type 2 diabetes, both sexes, age above 18-75 years old, all types of treatment, and willing to participate / give consent. investigators exclude patients who have been diagnosed as gestational diabetes, diabetes as a secondary cause, complication of ckd stage 5, hba1c is less than 7.0% for past 1 year with ckd stage 1 or 2, no complications or complications with good control, having enough knowledge (had education before) and implemented good practice regarding diabetes management assessed by the research nurses, and disabled persons who need other person's support for daily living. the sample size was calculated and found 70. patients who meet the eligibility criteria will be introduced by physicians at the phcs, and the nurses will contact the patients at the phc. written informed consent (icfs) will be obtained from all the participants. protocol including icfs got approval from the institutional review board of bangladesh medical research council (bmrc/nrec/2022-2025/336) on september 08, 2024. the outcome of this study is to evaluate the effects of telenursing intervention by controlling hba1c. investigators set various secondary endpoints including feasibility. by making self-supported decisions, the patients will be able to manage their diet, exercise and medication.


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed as type 2 diabetes * both sexes * age18-75 years old * who will have a smartphone or mobile phone * who are willing to participate / give us the consent exclusion criteria: * patients who have been diagnosed as type 1 and gestational diabetes * patients whose diabetes is secondary causes * patients who have complication of ckd stage 5 * patients whose hba1c is less than 7.0% past 1 year with ckd stage 1 or 2, no complications or complications with good control, having enough knowledge (had education before) and implemented good practice regarding diabetes management assessed by the research nurses (hereafter "the nurses") * disabled persons who need other person's support for daily living

Keywords: telenursing health education lifestyle modification diabetes